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Background: The purpose of this study was to investigate with neurophysiological and neuropsychological
methods such as pupillometry, cognitive test and Hamilton Depression Rating Scale (HAM-D) the hypothesis
of Central Nervous System (CNS) cholinergic involvement in patients with Myasthenia Gravis (MG).
Methods: Thirty-two patients (32) with MG and a mean age of 51.1 ± 17.2 volunteered to participate in this in-
vestigation, while thirty-three (33) healthy subjects with a mean age of 50.2 ± 14.8 served as controls. All sub-
jects underwent pupillometric measurements and performed the Wechsler Memory Scale (WMS) and HAM-D.
The pupillometric indices studied were: 1) latency for the onset of constriction (T1), 2) maximum constriction
velocity (VCmax) and 3) maximum constriction acceleration (ACmax).
Results: T1was found signiﬁcantly increased by 21.7% (p b 0.05) inMG patients as compared to healthy subjects.
Conversely, VCmax and ACmax were signiﬁcantly decreased in MG patients by 33.3% (p b 0.05) and 43.5%
(p b 0.05) respectively, as opposed to healthy subjects. Additionally, MG patients showed signiﬁcantly decreased
score inWMS by 41.6% (p b 0.05) as compared to healthy controls. No signiﬁcant difference was found for HAM-D
between the two groups.
Conclusions:VCmax andACmax are governedmainly by the action of the Parasympathetic Nervous System, through
acetylcholine. The results of this study demonstrate that the CNSmay be affected inMG and support the hypothesis
that MG has central cholinergic effects manifested by cognitive dysfunction.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Myasthenia gravis (MG) is an autoimmune disease with increasing
incidence per year. The prevalence rate of MG range from 15 to 179
cases per million worldwide [1] and Greece is reported to be among
the countries with the highest one [2]. MG is widely considered to be
a disorder of the neuromuscular junction, while the Central Nervous
System (CNS), cardiac and smooth muscles remain unaffected [3]. MG
is characterized by ﬂuctuating fatigue and muscle weakness [4], which
symptoms in some patients are limited to ocular muscles, while in
others, there is an expansion to the rest of themuscles. Abnormal fatiga-
bility of voluntary muscles results from a reduced number of functional
nicotinic acetylcholine receptors (AChRs) at the neuromuscular junction
[5]. Nicotinic AChRs are found in the central, as well as in the peripheral
nervous system, particularly in the hippocampus, hypothalamus, mid-
brain and cerebral cortex. It has been established that the central cholin-
ergic system is important in mediating cognitive processes of learning
and memory [5] and this is interesting because it may explain the factauth.gr (A. Kaltsatou).
. This is an open access article underthat the development of fatigue is associated with impairment cognitive
performance in these patients.
This assumption has led many studies to support the hypothesis of
CNS cholinergic involvement in MG [3,6], which suggests that MG has
central cholinergic deﬁcits manifested by cognitive dysfunction [6].
Also, various investigations have proposed that the CNS and the non-
striated muscles might be affected in MG. Moreover, reports of REM
sleep reduction [7], memory dysfunction [6], and detection of AChRs-
antibodies in the cerebrospinal ﬂuid conﬁrmed the hypothesis of CNS
involvement in MG [8]. Thus, if CNS involvement does occur in MG, it
might reasonably be expected tomanifest itself in certain abnormalities
of cognition in view of the evidence of the role of cholinergic transmis-
sion in attention and memory.
Then again, evidence for CNS involvement in MG is remarkably
unconvincing [9]. According to Marra et al. [10], impairments of atten-
tion, memory, and control tasks in MG are related to general visual
motor slowness and to the concomitant presence of other diseases
and not to cholinergic involvement in MG. Moreover, Sitek et al. [11]
suggested that impaired performance on some cognitive measures in
MG should be interpreted as an effect of muscle fatigability rather
than CNS involvement. Thus, it remains unclear as to whether MG af-
fects the CNS.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Descriptive statistics and comparison between myasthenic patients and healthy subjects
for all variables.
Variables MG patients
(n = 32)
Healthy subjects
(n = 33)
MG vs. healthy
p-Value⁎
Mean ± s.d. Mean ± s.d. p b 0.05
Demographic characteristics
Males/females 15/17 16/17 –
Age 51.1 ± 17.2 50.2 ± 14.8 0.086
Educational level (yrs) 7.9 ± 3.2 8.1 ± 4.1 0.16
Disease duration (yrs) 2.9 ± 0.2 – –
Cognitive test and Hamilton Depression Rating Scale
Wechsler Memory Scale 43.4 ± 4.7 74.4 ± 8.0 b0.001*
Hamilton Depression
Rating Scale
6.6 ± 1.1 7.0 ± 6.8 0.091
Pupillometric parameters
T1 0.28 ± 0.1 0.23 ± 0.2 b0.001*
ACmax 13.9 ± 3.2 24.6 ± 3.3 b0.001*
VCmax 1.6 ± 0.4 2.4 ± 0.2 b0.001*
T1: Latency for the onset of constriction, ACmax: Maximum constriction acceleration,
VCmax: Maximum constriction velocity.
⁎ p b 0.05 considered signiﬁcant.
300 A. Kaltsatou et al. / BBA Clinical 3 (2015) 299–303However, it has been emphasized by Paul et al. [12] the need for
more studies with sufﬁcient methodological approaches, which will in-
vestigate the cholinergic hypothesis in MG. Thus, the aim of this study
was to examine with established neurophysiological and neuropsycho-
logicalmethods, such as pupillometry and concomitantlywith cognitive
test and Hamilton Depression Rating Scale (HAM-D), the hypothesis of
CNS cholinergic involvement in patients with MG.
2. Material and methods
2.1. Subjects
Thirty-two (32) patients with a mean age 51.1 ± 17.2 years and di-
agnosed with MG volunteered to participate in this study, while thirty-
three (33) healthy subjects with a mean age 50.2 ± 14.8 served as con-
trols. The inclusion criteria for the present study were a deﬁnitive MG
diagnosis and clinical condition not worse than MGFA grade II during
the last year before participation. The mean time from the diagnosis
until the beginning of the study was 2.9 ± 0.2 years. Speciﬁcally, their
diagnosis was based on the one hand on the clinical symptoms (fatigue
during the day, etc.), and on the other hand, on the laboratory ﬁndings
(the presence of positive antibodies for the AchR, positive response at
the repeated stimuli test). Apart from these,MG patients showed an im-
provement of muscle strength following the intake of edrophonium
chloride and reacted positively to Mestinon.
All patients were free of any other neurological, ophthalmological,
physical or mental disease and their visual acuity, corrected or not,
was 20/20. Moreover, they had symmetrical pupils and no past history
of ocular operations or diseases affecting the pupil and were not being
treated at that time with anticholinergics, steroids, sympathomimetics,
β-blockers or other agents affecting the pupil light reﬂex (PLR). Also, the
basic precondition for participation was a mini mental score ≥22. All
measurements were performed between 09.00 am and 10.00 am, after
the participants had had a full 8-h sleep.
The whole study was conducted in the A Neurology Clinic of AHEPA
University Hospital of Aristotle University of Thessaloniki. All partici-
pants were informed about the study procedure and provided written
informed consent and all the experiments were approved by the Ethical
Committee of the AHEPAUniversity Hospital based on theHelsinki Dec-
laration. At the entry of the study all participants underwent a neuro-
psychological evaluation with pupillometry, Wechsler Memory Scale
(WMS) and HAM-D. All participants were assessed on a single occasion
only.
2.2. Pupillometry
Pupillary measurements were taken with a monocular and fully au-
tomated system that includes the following:
1) A CCD high-speed digital camera, which is capable of taking a max-
imum of 262 frames per second. The actual speed of the camera is
controlled by the software developed for this purpose. Because of
the corneal curvature and in order to avoid errors due to optical dis-
tortion, the camera is set normal to the axis of the eye and at a dis-
tance of 30 cm away, so that the image of the pupil is symmetrical.
2) A computer and the associated sampling cards
3) Two independent light sources: a) an infrared light source which
illuminates the face of the subject, consisting of an array of 32 LED
with a maximum intensity of 820 nm wavelength and is switched
on permanently throughout themeasurement and b) a clinical photic
stimulator (SLE) made by Biologic Systems Corporation U.K., which
activates a diffuse ﬂashlight of 20 ms duration and 24.6 cd/m2
intensity
4) A traversing mechanismwith a ﬁxed camera on a mechanismwhich
canmove in the three x–y–z directionswith also, a capability to rotate
the camera on both the x–y and the x–z planes5) An image processing system, which calculates the parameters of the
PLR in real time. The recordings of these parameters cease automati-
cally after 3.5 s from the application of ﬂash-light.
The accuracy of measurements depends on the number of pixels
covered by the pupil, which depends upon the optics of the system. In
the present case, the pupil covers about 120 × 120 pixels, so the accura-
cy of measurement of distance is ±0.62%. This leads to a spatial resolu-
tion in both the x and y directions of 0.015mm. The temporal resolution
is 2 ms [3].
Participants remained for 2 min in darkness, and 5 ﬂashes were ad-
ministered afterwards (inter-stimulus interval was 30 s). Stimulus du-
ration was 20 ms, and the luminance 24.6 cd/m2. Each eye was tested
separately. The ﬂash was placed at a distance of 30 cm from the eye.
Both healthy and myasthenic participants performed the experiment
with proper cooperation.
The following pupillometric parameters were measured:
1) Latency for the onset of constriction (T1), which is an index of
sympatho-vagal balance, since it is involved in the second seg-
ment of the V-shaped pupillometric response [13]. According to
Bergamin et al. [14] T1 is deﬁned at the time of maximum con-
striction acceleration;
2) Maximum constriction velocity (VCmax), which is a sensitive
index of Parasympathetic Nervous System (PNS) activity [13,15].
3) Maximum constriction acceleration (ACmax), which is modulat-
ed by PNS activity [13,15].
2.3. Cognitive tests and HAM-D
2.3.1. Wechsler Memory Scale (WMS)
The Greek version of the WMS [16] was used to evaluate the pa-
tients' different memory functions. WMS is an established neuropsy-
chological test, which evaluates patient' memory functions in relation
to other cognitive abilities and it is the most frequently used standard-
ized measure of memory function.
2.3.2. Hamilton Depression Rating Scale (HAM-D)
The severity of depression was assessed with the 17-item HDRS,
which is one of the most widely used observer-rated instruments to as-
sess the severity of depressive symptoms. The Greek version of the
HAM-D was used. Eight items are scored from 0 to 2 and nine items
are scored from 0 to 4. A cut-off point of 17 is often used to ensure a de-
gree of depression severity [17].
Fig. 1. Typical pupil light reﬂex curve of a myasthenic patient (A) and a non-myasthenic male (B) of matching age and gender.
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Fig. 2. Cognitive test and Hamilton Depression Rating Scale results.
a) reaction time (T1) 
b) ACmax and VCmax results
Fig. 3. Pupillometry results: a reaction time(T1).
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Data were analysed with Statistical Package for Social Sciences
(SPSS, Chicago, Illinois, USA), version 20.0 software for Windows. The
Kolmogorov–Smirnov test was used to examine the normality of the
distribution. Changes of variables within the groups at baseline and
the end of the study were evaluated by a One-Way ANOVA with
group being the independent variable. The signiﬁcance level was
p b 0.05. Finally, the Pearson correlation was calculated between each
pair of pupillometric parameters for each patient group and for the
total group of the healthy people. Moreover, the correlation of each
pupillometric parameter with age was also estimated. Curve analysis
(ROC) was performed in order to illustrate the classiﬁcation and dis-
crimination accuracy of the pupillary light reﬂexes. The area under the
curve (AUC) of the ROC curves was estimated and used as the index of
classiﬁcation accuracy, where a variable with an AUC= 1 indicates ex-
cellent discrimination ability into the myasthenic or healthy group
while a variablewith anAUCnear 0.5 indicates poor discrimination abil-
ity into the two groups.
3. Results
Descriptive statistics of all variables are presented in Table 1. MG
patients and controls were comparable for age, educational level, and
gender. No signiﬁcant differences were found for age and HAM-D be-
tween the two groups. Also, patients with MG had abnormal pupillary
function as compared to healthy subjects. Speciﬁcally, the mean value
of T1 was found signiﬁcantly increased by 21.7% (p b 0.05) in MG pa-
tients as compared to healthy subjects. Conversely, the mean scores of
VCmax and ACmax were signiﬁcantly decreased in MG patients by
33.3% (p b 0.05) and by 43.5% (p b 0.05), respectively, as compared to
healthy subjects. Patients with MG had decreased score in WMS by
41.6% (p b 0.05) compared with healthy subjects. Moreover, WMS
score was correlated with the pupillometric indexes of ACmax (r =
0.602, p b 0.05) and VCmax (r=0.578, p b 0.05). In Fig. 1 the PRL is pre-
sented for a non-myasthenic male (a) and amyasthenic patient (b). See
Figs. 2 and 3
ACmax and VCmax were the best predictors in discriminating a
subject as myasthenic or healthy with perfect classiﬁcation ability
(AUC = 1). Also, T1 had perfect classiﬁcation ability (AUC = 0.945).
4. Discussion
In the present investigation, the hypothesis concerning a central
cholinergic receptor's deﬁcit in MG patients was studied using neuro-
physiological and neuropsychological methods. The results of this
study demonstrated that MG patients exhibited a decreased cholinergic
activity, indicating that MG affects the cholinergic system and leads to
reduced cognitive performance.
Pupillometry is a valid and low-cost method for the evaluation of
ANS activity [18–20]. The pupil is controlled by two kinds of muscles
whose innervations are different: the iris sphincter is innervated by
the PNS, and the iris dilator, by the Sympathetic Nervous System
(SNS). Therefore, pupillometry has a potential to allow independent
evaluation of both types of ANS activity [18,20]. Accordingly, changes
in the pupil size can be used to assess the PNS and SNS neurotransmit-
ters' function, ACh and noradrenaline, respectively, within the CNS [18,
20].
ACmax and VCmax are considered to be extremely sensitive indica-
tors of cholinergic activity [3]. Yamazi et al. [13] had divided the charac-
teristic V-shaped response of the pupillary light reﬂex into three
segments: the ﬁrst is due exclusively to PNS excitation, the second is
controlled by both SNS and PSN and the latter reﬂects only SNS activity.
Hence, there is evidence that the parameters involved in the ﬁrst seg-
ment, such as ACmax and VCmax, are sensitive indicators of cholinergic
activity. According to our data, there was a signiﬁcant decrease inVCmax and ACmax in MG patients, leading to the hypothesis that
there is a central cholinergic deﬁcit inMG. Our results are in accordance
with other studieswhich support thatMG affects the cholinergic system
[6].
The signiﬁcant decrease of the acceleration and the velocity ascer-
tains the cholinergic deﬁcit, since ACh is considered the main neuro-
transmitter in the pupil movement. It could be supported that ACh is
the fuel of this movement and its deﬁcit results in the deceleration
of the motion of the pupil in response to light stimulus. Decreased
ACmax and VCmax in patients with MG have been previously reported
in a study by Tsiptsios et al. [3], supporting the CNS cholinergic deﬁcit
hypothesis. None of the 32 patients who underwent pupillometry
complained for disturbances in adjustment to light or to darkness.
Besides, all patients underwent the ophthalmologic examination test
with success. This means that the decrease of ACh does not inﬂuence
the motion of the pupil to the extent that it could cause difﬁculties of
adjustment for the patient or pathologic ﬁndings in the clinical
303A. Kaltsatou et al. / BBA Clinical 3 (2015) 299–303ophthalmologic examination. The hypothesis concerning CNS involve-
ment in MG is based on concurrent incidence of MG and multiple scle-
rosis, a prototypic autoimmune disease of the CNS, implicating a
common pathogenic mechanism for the two diseases [21–23]. Thus, ac-
cording to the aforementioned, the hypothesis concerning a central
cholinergic receptor's deﬁcit in MG is supported and the use of VCmax
and ACmax as the most sensitive indicators of this deﬁcit is conﬁrmed.
Moreover, MG patients signiﬁcantly displayed more difﬁculties in
cognitive abilities as revealed by their lower performance at the WMS.
These patients may have a degree of difﬁculty to memory functions in
relation to other cognitive abilities. This indicates the existence of
some cognitive dysfunction inMG patients, which has also been report-
ed in other studies [24,25]. In addition, the HAM-D was used to assess
the severity of depressive symptoms and to exclude this bias, because
typical depression in older adults is usually associated withmild reduc-
tions in cognitive functioning.
However, this is the ﬁrst study that has dealt with the PLR to single
Flash Stimuli and cognitive tests in MG. The fact that cholinergic deﬁcit
was observed in MG patients combined with the important role that
nicotinic AChRs in the hippocampus, hypothalamus and cerebral cortex
play in higher cognitive functions, supports the CNS involvement
hypothesis.
5. Conclusions
In conclusion, this is the ﬁrst investigation that has dealt with the
pupillary light reﬂex to single Flash Stimuli and the concomitant use
of the WMS in MG. The results proposed that the Central Cholinergic
System and/or the iris sphincter smooth muscle might be affected. Fur-
thermore, cognitive dysfunction was observed in patients with MG. Fi-
nally, it is suggested that pupillometry used concomitantly with the
WMS contributes to the elucidation and understanding of the psycho-
physiological bases of MG.
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